ALC-0315

ALC-0315
Names
	Other names ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate)
Identifiers
CAS Number	2036272-55-4;
3D model (JSmol)	Interactive image;
PubChem CID	122666778;
UNII	AVX8DX713V;
	InChI InChI=1S/C48H95NO5/c1-5-9-13-17-19-27-37-45(35-25-15-11-7-3)47(51)53-43-33-23-21-29-39-49(41-31-32-42-50)40-30-22-24-34-44-54-48(52)46(36-26-16-12-8-4)38-28-20-18-14-10-6-2/h45-46,50H,5-44H2,1-4H3 Key: QGWBEETXHOVFQS-UHFFFAOYSA-N;
	SMILES CCCCCCCCC(CCCCCC)C(=O)OCCCCCCN(CCCCO)CCCCCCOC(=O)C(CCCCCC)CCCCCCCC;
Properties
Chemical formula	C48H95NO5
Molar mass	766.290 g·mol−1
	Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
	Infobox references

ALC-0315 (((4-Hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate)) is a component of the lipid mixture used in the SARS-CoV-2 vaccine, BNT162b2, from BioNTech and Pfizer to form lipid nanoparticles.

ALC-0315 is a physiological pH cationic synthetic lipid that can be used together with other lipids to form lipid nanoparticles (LNPs).[1]

These nanoparticles promote the uptake of therapeutically effective nucleic acids such as oligonucleotides or messenger RNA both in vitro and in vivo. [2][3]

References

Medicines and Healthcare products Regulatory Agency (11 December 2020). "Public Assessment Report: Authorisation for Temporary Supply COVID-19 mRNA Vaccine BNT162b2" (PDF).
mRNA-based therapeutics — developing a new class of drugs, Ugur Sahin, Katalin Karikó and Özlem Türeci, Nature Reviews Drug Discovery, 13, 759-780 (2014), doi:10.1038/nrd4278.
mRNA vaccines — a new era in vaccinology, Norbert Pardi, Michael J. Hogan, Frederick W. Porter and Drew Weissman, Nature Reviews Drug Discovery, 17, 261-279 (2018), doi:10.1038/nrd.2017.243.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.